Efficacy and safety of biapenem in treatment of infectious disease: a meta-analysis of randomized controlled trials

J Chemother. 2016;28(1):28-36. doi: 10.1179/1973947814Y.0000000226.

Abstract

Background: Biapenem is a parenteral carbapenem antibiotic that has powerful antibacterial activity. The aim of this study is to evaluate the efficacy and safety of biapenem for the treatment of infection diseases.

Methods: We performed a meta-analysis of published randomized-controlled trials (RCTs) identified in Embase, PubMed, and Cochrane library that compared the efficacy and safety of biapenem with other antibiotic regimes for the treatment of patients with infections.

Results: Eight RCTs were included in the meta-analysis, involving totally 1685 patients with lower respiratory tract infections (LRTIs), complicated urinary tract infections (cUTIs), and complicated intra-abdominal infections (cIAIs). There was no difference found between the patients with LRTIs, cUTIs, or cIAIs treated with biapenem and comparators, regarding treatment success and adverse events.

Conclusion: This meta-analysis provides evidence that biapenem can be used as effectively and safely as imipenem-cilstatin or meropenem, for the treatment of patients with LRTIs, cUTIs, and cIAIs. It may be a considerable option for the treatment of these infections.

Keywords: Biapenem; Infection; Meta-analysis.

Publication types

  • Meta-Analysis

MeSH terms

  • Anti-Infective Agents / therapeutic use*
  • Communicable Diseases / drug therapy*
  • Humans
  • Randomized Controlled Trials as Topic*
  • Safety
  • Thienamycins / therapeutic use*
  • Treatment Outcome

Substances

  • Anti-Infective Agents
  • Thienamycins
  • biapenem